Trial Profile

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitric oxide (Primary) ; Antineoplastics
Indications Skin cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Proof of concept
Sponsors Beyond Air

Most Recent Events

10 Feb 2025 According to a Beyond Cancer media release, topline data from the Phase 1b portion of the study are anticipated late in calendar 2025 or early-2026.
03 Dec 2024 According to a Beyond Cancer media release, the company announced that topline data from the Phase 1b portion of the study are anticipated in the second half of 2025.
03 Dec 2024 Planned number of patients changed from 38 to 58.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com